Clinical Research Directory

Inclusion Criteria: * Voluntary written informed consent signed prior to any study-related procedures. * Age between 45 and 80 years (inclusive) at the time of screening. * Classified as "metabolically neglected" with documented pre-disease conditions or regulated early-stage chronic disorders. * Accelerated biological aging rate 1.1, OR between 1.05 and 1.099 combined with chronic low-grade inflammation (inflammaging). * Preserved cognitive function with a Montreal Cognitive Assessment (MoCA) score between 24 and 30 points. * Physical ability to perform computerized cognitive tests on a touch-screen tablet. * Commitment to maintaining stable dietary and physical activity habits throughout the study period. * Possession of a home freezer and ability to strictly comply with cold-chain storage logistics for investigational products and stool samples. * Demonstrated ability to swallow large capsules. * Adequate baseline laboratory parameters (such as blood counts and kidney function). * For women of childbearing potential: agreement to use a highly effective method of contraception throughout the study and for 30 days post-intervention. * Readiness to ensure presence at the registered home address to receive scheduled frozen-chain courier shipments. Exclusion Criteria: * Systemic antibiotic therapy within 12 weeks prior to baseline. * Supplementation with any commercial pre- or probiotics within 4 weeks prior to baseline. * Diagnosed malignancy within the past 5 years (except fully cured basal cell carcinoma or cervical cancer in situ). * Participation in any other clinical study or trial within 30 days prior to consent or during this study. * Pregnancy, breastfeeding, or planning a pregnancy during the study and for 30 days post-intervention. * Known hypersensitivity, intolerance, or allergy to any component of the investigational product (MBiotix HBI Caps), placebo, preparation antibiotics (Neomycin, Metronidazole), antibiotic placebo, or bowel cleansing solution (macrogols). * Pre-existing hearing loss, chronic tinnitus, or diagnosed vestibular disorder. History of or active peripheral neuropathy of any etiology. * Myasthenia gravis or other neuromuscular transmission disorders. * Concurrent, ongoing use of loop diuretics, other aminoglycoside antibiotics, or known nephrotoxic drugs. * Severe, unstable, or uncontrolled comorbidities, including NYHA Class III/IV heart failure, unstable angina, or myocardial infarction within the past 6 months. * Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR \< 30 mL/min/1.73 m²). * Active, severe psychiatric disorders (e.g., severe depression with active suicidal ideation, psychotic disorders, unstable bipolar disorder). Diagnosis of progressive neurodegenerative diseases (Parkinson's, Alzheimer's) or moderate-to-advanced dementia. * Active, clinically significant inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other severe gastrointestinal disorders. * Evidence of gastrointestinal mucosal damage (ulceration, perforation, bleeding) within 7 days prior to the first product dose. * Clinically significant immunosuppression, including chronic systemic corticosteroids, HIV infection with a CD4+ cell count \< 200/µl, history of solid organ or hematopoietic stem cell transplantation. * Active infection requiring antibiotics during the induction phase or anticipated antibiotic use during the first 7 days post-induction. * Prior fecal microbiota transplantation (FMT) treatment for indications other than recurrent C. difficile infection. * Significant dysphagia precluding safe capsule ingestion. * Inadequate baseline laboratory parameters (such as blood counts and kidney function). * Any medical condition or circumstance judged by the Principal Investigator to compromise participant safety or protocol adherence. * Anticipated inability to comply with study procedures, such as missing scheduled follow-up visits, lacking reliable home freezer storage, or having a lifestyle/occupation that prevents proper cold-chain product handling or consistent attendance.